Over the 4 study years, we noted a possible trend of decreasing utilization of ICI monotherapy, which could be attributable to decreased patient numbers in 2020 or secondary to an increase at our academic center in ICI-based clinical trial options that enrolled immunotherapy-naïve patients, who were thus excluded from this observational study.
← all excerpts
PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017-2021.
1
—
—